27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The APOE-4 allele increases risk and decreases age at onset of PD, an association that may not be dependent upon cognitive impairment. 3 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
AD biomarkers are useful to predict AD-type dementia in subjects with aMCI and naMCI. 4 key findings →
Participants: 231 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Lowering brain Aβ must be accomplished early in the evolution of AD. 4 key findings →
Participants: 475 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Biomarker trajectory shapes by MMSE score were complex and were affected by interactions with age and APOE status. 3 key findings →
Design: cross-sectional Participants: 343 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The CSF levels of Aβ42 but not total and phosphorylated tau were lower in APOE ε4 carriers compared with noncarriers irrespective of diagnostic group (cohort A). 3 key findings →
Participants: 105 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
AD patients with ELA expressed significantly greater levels of APOE than ALA APOE ε4 carriers. 3 key findings →
Participants: 60,908 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
APOE epsilon4 carrier status was associated with conversion to AD in older outpatients after controlling for known demographic and clinical risk factors, and APOE epsilon4 homozygosity was associated with increased risk of conversion to AD. 3 key findings →
Design: longitudinal study Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Furthermore, the CSF biomarker analyses provide a first insight into the potentially predominant pathogenetic mechanism(s) underlying the association between AD risk and PICALM. 1 key finding →
Design: case-control study Participants: 4,254 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cross-ancestry sex-stratified analyses identified several loci with evidence of interaction (p 0.05). 5 key findings →
Design: meta-analysis Participants: 25,284 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The study encompassed 479 723 participants (mean [SD] age, 56.5 [8.1] years; 260 730 females [54.4%]), including 271 690 in the YOD analyses and 334 939 in the LOD analyses. 5 key findings →
Design: cohort study Participants: 723 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
DSD is linked to adverse outcomes, compared to dementia alone, like longer hospitalisation [3], mortality [3, 4], functional decline [3] and need for residential care [3]. 4 key findings →
Design: systematic review Participants: 64 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In comparative high-throughput sequencing assays, a fundamental task is the analysis of count data, such as read counts per gene in RNA-seq, for evidence of systematic changes across experimental conditions.
Full summary, score breakdown and related studies → Original source Free full text
Apolipoprotein E is a plasma protein that serves as a ligand for low density lipoprotein receptors and, through its interaction with these receptors, participates in the transport of cholesterol and other lipids among various cells of the body.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Full summary, score breakdown and related studies → Original source Free full text
Full summary, score breakdown and related studies → Original source Free full text
UK Biobank is a major prospective epidemiological study, including multimodal brain imaging, genetics and ongoing health outcomes. 1 key finding →
Participants: 8,428 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) affects half the US population over the age of 85 and is universally fatal following an average course of 10 years of progressive cognitive disability. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
People's differences in cognitive functions are partly heritable and are associated with important life outcomes. 5 key findings →
Participants: 36 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We retrospectively assessed the diagnostic accuracy of whole genome sequencing to detect the most common repeat expansion loci associated with neurological outcomes (AR, ATN1, ATXN1, ATXN2, ATXN3, ATXN7, C9orf72, CACNA1A, DMPK, FMR1, FXN, HTT, and TBP) using samples obtained within the National Health Service in England from patients who were suspected of having neurological disorders; previous PCR test results were used as the reference standard. 4 key findings →
Participants: 3,000 Evidence: low
Full summary, score breakdown and related studies → Original source
To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has largely focused on the removal of amyloid beta Aβ fragments from the CNS. 4 key findings →
Participants: 59 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Genome-wide association studies (GWAS) have identified >80 Alzheimer's disease and related dementias (ADRD)-associated genetic loci. 3 key findings →
Participants: 7,804 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common form of dementia and a growing public health burden in the United States. 5 key findings →
Participants: 1,515 Evidence: low
Full summary, score breakdown and related studies → Original source
Although abnormal accumulation of amyloid in the brain is an early biomarker of Alzheimer's disease (AD), wide variation in cognitive trajectories during life can be seen in the setting of brain amyloidosis, ranging from maintenance of normal function to progression to dementia. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Higher GRS predicted mortality (hazard ratio = 1.05; 95% confidence interval: 1.00-1.10, P = .04). 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Arousal affects cognition, emotion, and behavior and has been implicated in the etiology of psychiatric disorders. 5 key findings →
Participants: 1,877 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →